-
Jul 23, 2024 | 
conexiant.com | Vaibhav Sadhamta |Puyaan Singh
Merck's antibody-based drug MK-1654 met the primary endpoint in a phase II/III trial for the prevention of respiratory syncytial virus in infants, the company announced. The injected treatment significantly reduced the incidence of lower respiratory tract infections in infants compared to placebo and met the study's safety objectives. Merck plans to submit the trial data to global regulatory authorities and will present detailed findings at an upcoming scientific congress.
-
Apr 26, 2024 | 
aol.com | Mariam Sunny |Vaibhav Sadhamta
April 26, 2024 at 12:04 PMBy Mariam Sunny and Vaibhav Sadhamta(Reuters) -Centene said on Friday its Medicare insurance business would face several challenges next year, taking the sheen off a strong first-quarter earnings report from the health insurer.
-
Apr 26, 2024 | 
reuters.com | Mariam Sunny |Vaibhav Sadhamta
April 26 (Reuters) - Centene Corp (CNC.N), opens new tab raised its annual profit forecast and beat Wall Street estimates for first-quarter profit on Friday, as higher premiums from commercial insurance plans helped keep its medical costs in check. The health insurer also posted an over 35% jump in its commercial memberships, sending the shares of the company up 4.4% in premarket trade.
-
Apr 26, 2024 | 
today.westlaw.com | Shinjini Ganguli |Mariam Sunny |Vaibhav Sadhamta
(Reuters) -Centene Corp raised its annual profit forecast and beat Wall Street estimates for first-quarter profit on Friday, as higher premiums from commercial insurance plans helped keep its medical costs in check. The health insurer also posted an...
-
Mar 28, 2024 | 
today.westlaw.com | Subhranshu Sahu |Pratik Jain |Vaibhav Sadhamta |Mrinmay Dey
(Reuters) -The U.S. Food and Drug Administration approved Akebia Therapeutics' drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialysis patients, the drugmaker said on Wednesday. The drug will be available under the brand...
-
Feb 20, 2024 | 
streetinsider.com | Christy Santhosh |Vaibhav Sadhamta
By Christy Santhosh and Vaibhav Sadhamta(Reuters) -Medical device maker Medtronic raised annual profit forecast for the third time this fiscal year, after beating third-quarter expectations on Tuesday, helped by higher demand for its heart and diabetes devices. Demand for medical devices has picked up pace as non-urgent procedures, which were deferred during the pandemic, recovered in the past year with easing hospital staff shortages and people becoming regular with check-ups.
-
Feb 6, 2024 | 
today.westlaw.com | Mariam E Sunny |Krishna Eluri |Vaibhav Sadhamta
(Reuters) -Centene Corp beat Wall Street estimates for fourth-quarter revenue on Tuesday, on the back of higher premiums in its commercial insurance business. The health insurer's quarterly profit, however, only narrowly beat estimates as medical...
-
Dec 27, 2023 | 
zawya.com | Vaibhav Sadhamta
Credit ratings agency Fitch lowered its rating on Ethiopia's long-term foreign-currency debt on Wednesday after the east African country failed to pay a coupon on its single outstanding $1 billion Eurobond. Fitch cut Ethiopia's long-term foreign-currency issuer default rating to "RD" from "C", and had earlier this month downgraded its rating on Africa's second-most populous country to "C" from "CC", citing an increased likelihood of default.
-
Nov 9, 2023 | 
srnnews.com | Pratik Jain |Vaibhav Sadhamta
Takeda Pharma gets US FDA approval for rare blood disorder therapy By Pratik Jain and Vaibhav Sadhamta(Reuters) -The U.S. Food and Drug Administration on Thursday approved Takeda Pharmaceutical’s therapy to treat a rare genetic blood disorder in adult and pediatric patients. Takeda’s Adzynma becomes the first treatment available to patients with congenital thrombotic thrombocytopenic purpura (TTP).
-
Nov 7, 2023 | 
egyptdailynews.com | Vaibhav Sadhamta |Shailesh Kuber
(Reuters) - Ratings agency Fitch downgraded Egypt's long-term foreign-currency issuer default rating (IDR) to 'B-' from 'B', citing increased financial risks and higher government debt. The downgrade reflects increased risks to Egypt's external financing, macroeconomic stability and the trajectory of already-high government debt, the rating agency said.
